US Patent Issued to CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) on Feb. 4 for "Solid form, crystalline form, and crystal form a of FXR agonist, and preparation method and application thereof" (Chinese Inventors)

ALEXANDRIA, Va., Feb. 5 -- United States Patent no. 12,215,098, issued on Feb. 4, was assigned to CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co. LTD. (Hebei, China).

"Solid form, crystalline form, and crystal form a of FXR agonist, and preparation method and application thereof" was invented by Xiaolin Li (Shanghai), Peng Li (Shanghai) and Haiying He (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are a solid form, a crystalline form, and crystal form A of a compound of formula (I) used as an FXR agonist, and a preparation method therefor. Also comprised is an application of the compound of formula (I) in preparation of a medication for treating nonalcoholic steatohepatitis (NAS...